Market Place
Sourcing Support
Basilea returns cancer drug rights to Merck
28 Jun 2022 //
FIERCEBIOTECH
Basilea reports PC data on BAL0891, derazantinib and lisavanbulin at AACR
13 Apr 2022 //
GLOBENEWSWIRE
Basilea reports updated interim results for iCCA patients with FGFR2 inhibitor
24 Jan 2022 //
GLOBENEWSWIRE
Basilea presents preclinical data on synergy between derazantinib and paclitaxel
11 Oct 2021 //
GLOBENEWSWIRE
Basilea presents full safety and efficacy data set on derazantinib in ESMO
17 Sep 2021 //
GLOBENEWSWIRE
Basilea presents preclinical data on anti-angiogenic activity of derazantinib
26 Oct 2020 //
GLOBENEWSWIRE
Basilea reports interim results from ph1/2 study FIDES-02 exploring derazantinib
12 Oct 2020 //
GLOBENEWSWIRE
Basilea reports pooled efficacy data for derazantinib in iCCA patients FGFR2
12 Oct 2020 //
BASILEA
Basilea announces completion patient enrolment into first cohort of ph2 FIDES-01
20 Jul 2020 //
GLOBENEWSWIRE
Basilea initiates trial of derazantinib to treat urothelial cancer
13 Aug 2019 //
CLINICALTRIAL SERANA
Sinovant Sciences Announces Approval of Derazantinib’s Trial Application
30 Apr 2019 //
BUSINESSWIRE
NMPA approves Sinovant`s clinical trial application for Derazantinib
30 Apr 2019 //
BIOSPECTRUMASIA
Basilea slots ArQule FGF drug into its cancer portfolio
17 Apr 2018 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.